Immunization News and Research

RSS

Convalescent antibodies do not enhance SARS-CoV-2 infection

Researchers investigated whether antibodies enhance severe acute respiratory syndrome coronavirus-2 infection.

16 Mar 2022

New way to deliver potential HIV vaccine using mRNA technology

Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.

15 Mar 2022

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Researchers have been investigating the potential for vaccines and treatments against the nucleocapsid protein of SARS-CoV-2.

15 Mar 2022

Antimicrobial prescribing among infants may be prevented using maternal RSV vaccines

RSV is a leading cause of severe acute lower respiratory tract infections (LRTIs) among infants globally, and a prominent contributor to common non-severe infections that account for high volumes of antibiotic consumption.

14 Mar 2022

COVID-19 incidence in K-12 schools in mask-required vs. mask-optional settings

Researchers evaluate the impact of wearing facemasks by students in schools and the incidence of SARS-CoV-2 infection.

14 Mar 2022

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Researchers evaluated the efficacy of viral spike domain 2-specific human monoclonal antibodies delivered intranasally, against all beta coronaviruses in hamsters and mice.

11 Mar 2022

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection.

10 Mar 2022

Natural SARS-CoV-2 infection-induced anti-spike antibody responses

Researchers demonstrated the anti-spike antibody response to SARS-CoV-2 infection and further estimated the acute SARS-CoV-2 infection-induced Ab activity against recently emerged variants like Omicron.

10 Mar 2022

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Researchers explored strategies to develop an mRNA-based COVID-19 vaccine that could elicit safer and wider protection against SARS-CoV-2 variants of concern.

10 Mar 2022

The trajectory of B-cell immunity six months after mRNA vaccination

Researchers assess SARS-CoV-2 antibodies in individuals vaccinated with a mRNA COVID-19 vaccine six months after receiving their second dose.

10 Mar 2022

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

The new drug nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled phase 3 clinical trial published in the New England Journal of Medicine.

9 Mar 2022

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Researchers assessed the levels of neutralizing antibodies in coronavirus disease patients.

9 Mar 2022

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Researchers developed a vaccine candidate termed Ad26.COV2.S.529, encoding a stabilized Omicron-based S protein resembling ancestral SARS-CoV-2 Wuhan-Hu-1 S protein.

8 Mar 2022

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Researchers developed a highly thermo-tolerant vaccine candidate that elicited high nAb titers in mice against several SARS-CoV-2 variants of concerns.

8 Mar 2022

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

Researchers compared the immunogenicity of the reduced and standard doses of the BNT162b2 and mRNA-1273 vaccine in adults immunized with two doses of the CoronaVac vaccine.

8 Mar 2022

French study shows COVID vaccine efficacy 94% against severe outcomes

A recent paper published on the medRxiv preprint server utilized data from three national databases containing an abundance of information on Covid-19 screening (SI-DEP), vaccination (VAC-SI), and hospitalizations (SI-VIC) in France to provide additional perspectives on vaccine effectiveness and its evolution over the year 2021 in the French context.

7 Mar 2022

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled Phase 3 clinical trial.

3 Mar 2022

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

A new study assesses breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis.

3 Mar 2022

$The benefits of using fractional doses of COVID-19 vaccines$

The benefits of using fractional doses of COVID-19 vaccines

A new study published in PNAS assessed the benefits of using fractional doses for curbing the current COVID-19 pandemic.

3 Mar 2022

First dose SARS-CoV-2 vaccination coverage among younger children in America

Researchers recently investigated the differences in first dose coverage of coronavirus disease 2019 vaccination among children aged five to 11 years in the United States.

3 Mar 2022

Immunization News and Research

Convalescent antibodies do not enhance SARS-CoV-2 infection

New way to deliver potential HIV vaccine using mRNA technology

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Antimicrobial prescribing among infants may be prevented using maternal RSV vaccines

COVID-19 incidence in K-12 schools in mask-required vs. mask-optional settings

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Natural SARS-CoV-2 infection-induced anti-spike antibody responses

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

The trajectory of B-cell immunity six months after mRNA vaccination

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

French study shows COVID vaccine efficacy 94% against severe outcomes

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

The benefits of using fractional doses of COVID-19 vaccines

First dose SARS-CoV-2 vaccination coverage among younger children in America

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News